RxSight, Inc. (NASDAQ:RXST) Stock Position Raised by Jump Financial LLC

Jump Financial LLC boosted its position in shares of RxSight, Inc. (NASDAQ:RXST) by 57.2% during the 4th quarter, HoldingsChannel reports. The firm owned 93,255 shares of the company’s stock after buying an additional 33,934 shares during the quarter. Jump Financial LLC’s holdings in RxSight were worth $3,206,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of RXST. Mountain Capital Investment Advisors Inc. boosted its position in RxSight by 3.8% during the 4th quarter. Mountain Capital Investment Advisors Inc. now owns 8,779 shares of the company’s stock worth $302,000 after acquiring an additional 320 shares during the period. Wells Fargo & Company MN increased its stake in RxSight by 1.7% in the 4th quarter. Wells Fargo & Company MN now owns 26,574 shares of the company’s stock valued at $914,000 after buying an additional 445 shares during the period. Legal & General Group Plc lifted its position in RxSight by 1.2% in the 4th quarter. Legal & General Group Plc now owns 42,445 shares of the company’s stock worth $1,459,000 after buying an additional 512 shares in the last quarter. F M Investments LLC boosted its stake in shares of RxSight by 12.6% during the 4th quarter. F M Investments LLC now owns 5,901 shares of the company’s stock valued at $203,000 after buying an additional 659 shares during the period. Finally, LPL Financial LLC increased its stake in shares of RxSight by 3.6% in the fourth quarter. LPL Financial LLC now owns 25,007 shares of the company’s stock worth $860,000 after acquiring an additional 861 shares during the last quarter. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $17.00 target price (down from $40.00) on shares of RxSight in a research report on Friday, April 4th. Piper Sandler assumed coverage on shares of RxSight in a research report on Tuesday. They issued a “neutral” rating and a $18.00 target price for the company. Bank of America restated an “underperform” rating and set a $22.00 price target (down previously from $36.00) on shares of RxSight in a report on Thursday, April 3rd. Needham & Company LLC restated a “buy” rating and set a $43.00 target price on shares of RxSight in a report on Thursday, April 3rd. Finally, UBS Group downgraded RxSight from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $45.00 to $16.00 in a research note on Wednesday, April 9th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $37.60.

RxSight Trading Down 0.6 %

Shares of RXST stock opened at $14.43 on Friday. RxSight, Inc. has a 1 year low of $13.50 and a 1 year high of $66.54. The firm’s fifty day simple moving average is $24.13 and its 200 day simple moving average is $35.36. The firm has a market capitalization of $584.29 million, a P/E ratio of -17.39 and a beta of 1.26.

RxSight (NASDAQ:RXST) last released its earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.25). The company had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. Equities research analysts anticipate that RxSight, Inc. will post -0.7 EPS for the current fiscal year.

Insider Activity at RxSight

In other news, Director Shweta Maniar sold 3,519 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.87, for a total value of $108,631.53. Following the sale, the director now directly owns 7,383 shares in the company, valued at approximately $227,913.21. This represents a 32.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Tamara Fountain sold 7,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the transaction, the director now owns 24,793 shares of the company’s stock, valued at $637,428.03. This trade represents a 22.02 % decrease in their position. The disclosure for this sale can be found here. 9.36% of the stock is currently owned by corporate insiders.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.